Avalon GloboCareALBT
ALBT
About: Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Employees: 5
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
15% more funds holding
Funds holding: 13 [Q2] → 15 (+2) [Q3]
0.72% less ownership
Funds ownership: 2.29% [Q2] → 1.57% (-0.72%) [Q3]
67% less capital invested
Capital invested by funds: $119K [Q2] → $39K (-$80.1K) [Q3]
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for ALBT.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health monitoring.
Neutral
GlobeNewsWire
1 month ago
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving
FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with an exclusivity period of 120 days (the “Exclusivity Period”), during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the proposed strategic collaboration.
Positive
InvestorPlace
4 months ago
Why Is Avalon GloboCare (ALBT) Stock Up 173% Today?
Avalon GloboCare (NASDAQ: ALBT ) stock is up on Wednesday alongside news of a new medical device being launched by Laboratory Services MSO. Laboratory Services MSO is preparing to launch its GeeWhiz External Condom Catheter in the third quarter of 2024.
Neutral
GlobeNewsWire
4 months ago
Avalon's Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction
Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample Collection
Positive
Proactive Investors
6 months ago
Avalon GloboCare unveils KetoAir breathalyzer at KetoCon 2024
Avalon GloboCare Corp (NASDAQ:ALBT) said it had successfully launched its KetoAir breathalyzer in the US at the Hack Your Health by KetoCon 2024 Conference. Avalon CEO David Jin told shareholders that the booth at the event in Austin “attracted a diverse group of potential clients and partners, including doctors, disease management companies, health and keto coaches, consumers, keto product manufacturers, and service providers interested in establishing a marketplace on our app and device.
Neutral
InvestorPlace
6 months ago
Why Is Avalon Globocare (ALBT) Stock Down 27% Today?
Avalon Globocare (NASDAQ: ALBT ) stock is down on Tuesday but only after the commercial real estate company's shares underwent a massive rally on Monday on a recent filing. That rally came after the company filed its Form 10-Q with the Securities and Exchange Commission (SEC).
Neutral
GlobeNewsWire
6 months ago
Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report
FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”).
Positive
Proactive Investors
7 months ago
Avalon GloboCare launches KetoAir breathalyzer in the US
Avalon GloboCare Corp (NASDAQ:ALBT) officially unveiled its KetoAir breathalyzer device in the United States at the Hack Your Health by KetoCon 2024 Conference. Specifically engineered for ketogenic health management, KetoAir utilizes nano-sensor-based technology and AI algorithms to not only assess the user's ketosis status but also seamlessly record diet and exercise details into an app.
Neutral
GlobeNewsWire
8 months ago
Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference
FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.
Positive
Proactive Investors
8 months ago
Avalon GloboCare extends exclusive distribution agreement for KetoAir breathalyzer
Avalon GloboCare Corp (NASDAQ:ALBT) announced the extension of its exclusive distribution agreement with Qi Diagnostics for the KetoAir breathalyzer device and related accessories in several key regions, including North America, South America, the United Kingdom and the European Union. Shares of the biotechnology company added 19% at US$0.36 before Thursday's opening bell on the news.
Charts implemented using Lightweight Charts™